A2 Corp, which markets milk products with a protein variant claimed to have health benefits, had its shares halted from trading pending a statement.
The Sydney-based company, whose shares have more than doubled in the past 12 months, said last week it is in talks with the NZX about shifting its listing to the main board from the NZAX, a market for smaller companies and start-ups.
The shares traded at 67 cents yesterday, valuing the company at $399 million.
"A move to the NZX main board may provide greater liquidity and increase access to capital," managing director Geoffrey Babidge said last week.
Last month, the company completed a six-month strategic review and has embarked on plans to take control of its New Zealand marketing and accelerate its global expansion.
This article is tagged with the following keywords. Find out more about MyNBR Tags
Most listened to
- Zespri's Carol Ward talks about market challenges and innovation.
- Vanguard’s Robin Bowerman on the cluster bomb controversy
- In Editor's Insight, Nevil Gibson explains how revenue from streaming of music has doubled in a year
- BNZ CEO Anthony Healy on dairy lending and the bank's annual results
- NZ Oil & Gas chairman Rodger Finlay on exploration, capital and appointing a permanent CEO